Verve Therapeutics (VERV) Short Interest Ratio & Short Volume → This is the best new way to score with AI (From Weiss Ratings) (Ad) Free VERV Stock Alerts $6.38 +0.15 (+2.41%) (As of 04:00 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Verve Therapeutics Short Interest DataCurrent Short Volume16,540,000 sharesPrevious Short Volume15,690,000 sharesChange Vs. Previous Month+5.42%Dollar Volume Sold Short$99.41 millionShort Interest Ratio / Days to Cover12.6Last Record DateApril 30, 2024Outstanding Shares83,960,000 sharesFloat Size54,790,000 sharesShort Percent of Float30.19%Today's Trading Volume2,137,814 sharesAverage Trading Volume1,243,679 sharesToday's Volume Vs. Average172% Short Selling Verve Therapeutics ? Sign up to receive the latest short interest report for Verve Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatVERV Short Interest Over TimeVERV Days to Cover Over TimeVERV Percentage of Float Shorted Over Time Ad Weiss RatingsTiny AI projects with huge promise hiding in plain sight …I’ve developed a system that’s helped me find huge winners in the past. Now my system has alerted me to the next four altcoins that could be the next superstars.Click here to find out who they are. Verve Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202416,540,000 shares $99.41 million +5.4%30.2%12.6 $6.01 4/15/202415,690,000 shares $114.69 million +2.2%28.6%12.3 $7.31 3/31/202415,360,000 shares $203.98 million +8.9%28.0%12.3 $13.28 3/15/202414,100,000 shares $194.72 million +12.6%25.7%12.8 $13.81 2/29/202412,520,000 shares $213.47 million -0.6%22.9%11 $17.05 2/15/202412,590,000 shares $167.20 million +1.8%23.0%10.7 $13.28 Get the Latest News and Ratings for VERV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/202412,370,000 shares $133.84 million +0.1%21.9%7.7 $10.82 1/15/202412,360,000 shares $157.84 million +5.4%21.9%7.2 $12.77 12/31/202311,730,000 shares $163.52 million +4.4%22.9%7 $13.94 12/15/202311,240,000 shares $155.79 million -21.8%21.9%6.7 $13.86 11/30/202314,380,000 shares $162.21 million +7.7%28.0%9.2 $11.28 11/15/202313,350,000 shares $153.39 million +5.2%30.8%9.5 $11.49 10/31/202312,690,000 shares $152.79 million +11.1%29.6%13.2 $12.04 10/15/202311,420,000 shares $133.61 million -6.2%26.7%16 $11.70 9/30/202312,180,000 shares $161.51 million +2.0%28.4%18.2 $13.26 9/15/202311,940,000 shares $151.40 million +0.2%27.9%19.4 $12.68 8/31/202311,920,000 shares $153.41 million +6.7%28.2%18.6 $12.87 8/15/202311,170,000 shares $176.49 million +4.5%26.4%17.9 $15.80 7/31/202310,690,000 shares $219.04 million -10.2%26.5%17.2 $20.49 7/15/202311,900,000 shares $237.29 million +0.5%29.5%19.2 $19.94 6/30/202311,840,000 shares $222 million +2.5%29.3%18.3 $18.75 6/15/202311,550,000 shares $229.15 million -6.6%28.6%16.6 $19.84 5/31/202312,360,000 shares $191.33 million -1.9%30.6%17.8 $15.48 5/15/202312,600,000 shares $222.52 million -4.0%31.2%16.7 $17.66 4/30/202313,120,000 shares $209.00 million -2.3%34.5%17.5 $15.93 4/15/202313,430,000 shares $202.12 million -0.5%35.3%17.9 $15.05 3/31/202313,500,000 shares $194.67 million -1.5%35.6%18.3 $14.42 3/15/202313,700,000 shares $233.59 million No Change36.1%19.3 $17.05 2/28/202313,700,000 shares $260.30 million +1.0%36.1%17 $19.00 2/15/202313,570,000 shares $294.74 million +5.9%35.9%17.6 $21.72 1/31/202312,820,000 shares $291.66 million +0.2%31.6%13.9 $22.75 1/15/202312,790,000 shares $293.40 million +2.6%31.5%13.3 $22.94 12/30/202212,470,000 shares $241.29 million +13.8%32.5%13 $19.35 12/15/202210,960,000 shares $213.94 million +8.4%29.0%11.1 $19.52 11/30/202210,110,000 shares $234.86 million +1.3%26.7%9.4 $23.23 11/15/20229,980,000 shares $260.08 million -0.7%26.4%9.9 $26.06 10/31/202210,050,000 shares $378.89 million -6.3%26.9%9.6 $37.70 10/15/202210,730,000 shares $327.91 million -11.5%29.7%11.1 $30.56 9/30/202212,130,000 shares $416.67 million +23.0%33.6%10 $34.35 9/15/20229,860,000 shares $409.09 million +2.0%27.3%8.2 $41.49A ‘DeFi Summer’ Projected! (Ad)Top analysts are predicting DeFi coins to see massive gains in the coming months… During this dubbed ‘DeFi Summer…’ A coin that has been called the “DeFi pioneer” is poised to shoot up 3-7x!Just click here to learn how you can access this coin right now. VERV Short Interest - Frequently Asked Questions What is Verve Therapeutics' current short interest? Short interest is the volume of Verve Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 16,540,000 shares of VERV short. 30.19% of Verve Therapeutics' shares are currently sold short. Learn More on Verve Therapeutics' current short interest. What is a good short interest ratio for Verve Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. VERV shares currently have a short interest ratio of 13.0. Learn More on Verve Therapeutics's short interest ratio. Which institutional investors are shorting Verve Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Verve Therapeutics: PEAK6 Investments LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Verve Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 30.19% of Verve Therapeutics' floating shares are currently sold short. Is Verve Therapeutics' short interest increasing or decreasing? Verve Therapeutics saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 16,540,000 shares, an increase of 5.4% from the previous total of 15,690,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Verve Therapeutics' float size? Verve Therapeutics currently has issued a total of 83,960,000 shares. Some of Verve Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Verve Therapeutics currently has a public float of 54,790,000 shares. How does Verve Therapeutics' short interest compare to its competitors? 30.19% of Verve Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Verve Therapeutics: Astria Therapeutics, Inc. (10.24%), KalVista Pharmaceuticals, Inc. (13.13%), Applied Therapeutics, Inc. (3.91%), Y-mAbs Therapeutics, Inc. (7.47%), Travere Therapeutics, Inc. (16.83%), Aerovate Therapeutics, Inc. (10.43%), Arbutus Biopharma Co. (3.08%), IGM Biosciences, Inc. (29.87%), Larimar Therapeutics, Inc. (6.11%), Oculis Holding AG (0.20%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Verve Therapeutics stock? Short selling VERV is an investing strategy that aims to generate trading profit from Verve Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Verve Therapeutics? A short squeeze for Verve Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of VERV, which in turn drives the price of the stock up even further. How often is Verve Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VERV, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: Astria Therapeutics Short Interest Data KalVista Pharmaceuticals Short Interest Data Applied Therapeutics Short Interest Data Y-mAbs Therapeutics Short Interest Data Travere Therapeutics Short Interest Data Aerovate Therapeutics Short Interest Data Arbutus Biopharma Short Interest Data IGM Biosciences Short Interest Data Larimar Therapeutics Short Interest Data Oculis Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:VERV) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyWATCH: The Truth About InflationBirch Gold